Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis

被引:0
|
作者
Tjalf Ziemssen
机构
[1] Technical University of Dresden,Neurological University Clinic
[2] Medical Faculty “Carl Gustav Carus”,undefined
来源
Journal of Neurology | 2005年 / 252卷
关键词
multiple sclerosis; neurodegeneration; neuroprotection; inflammation; treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Historically considered to be an autoimmune demyelinating disease, multiple sclerosis is now recognized to be characterized by significant axonal and neuronal pathology. Addressing this neurodegenerative component of the disease is an important treatment objective, since axonal injury is believed to underlie the accumulation of disability and disease progression. The precise relationship between the inflammatory and neurodegenerative components in multiple sclerosis remains poorly elucidated, although neurodegeneration appears to be at least partially independent from neuroinflammation. The mechanisms underlying axonal injury appear complex and are likely to be multifactorial. Specific treatment strategies need to be developed that act within the central nervous system to prevent neurodegeneration and need to be provided from the earliest stages of disease. It is likely that immunomodulatory treatments acting purely in the periphery will provide only indirect and not direct neuroprotection. A promising approach is to enhance neuroprotective autoimmunity inside the brain, believed to be mediated, at least in part, by the release of neurotrophic factors within the nervous system from infiltrating immune cells. Such a beneficial process would be inhibited by a non-selective immunosuppressive strategy. In summary, treatments of multiple sclerosis should take into account the heterogeneous pathophysiology of the disease. The pathogenic process in the central nervous system itself should be the major focus in multiple sclerosis therapy in order to protect against demyelination and axonal loss and to promote remyelination and regeneration directly in the target tissue, independently of peripheral immune status. In conclusion, selective treatment strategies aimed at preventing axonal injury within the central nervous system are required to complement existing, peripherally acting treatments targeting the immune system.
引用
收藏
页码:v38 / v45
相关论文
共 50 条
  • [1] Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis
    Ziemssen, T
    JOURNAL OF NEUROLOGY, 2005, 252 (Suppl 5) : V38 - V45
  • [2] Multiple sclerosis and central nervous system remyelination
    Lubetzki, C
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2003, 187 (04): : 699 - 707
  • [3] Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System
    Galetta, Kristin M.
    Bhattacharyya, Shamik
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (02) : 325 - +
  • [4] MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system
    Filippi, M
    Rocca, MA
    JOURNAL OF NEUROLOGY, 2005, 252 (Suppl 5) : V16 - V24
  • [5] MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system
    Massimo Filippi
    Maria Assunta Rocca
    Journal of Neurology, 2005, 252 : v16 - v24
  • [6] Exercise as a Countermeasure to Declining Central Nervous System Function in Multiple Sclerosis
    Mot, Robert W.
    Sandroff, Brian M.
    CLINICAL THERAPEUTICS, 2018, 40 (01) : 16 - 25
  • [7] Infiltration by monocytes of the central nervous system and its role in multiple sclerosis: reflections on therapeutic strategies
    Zhang, Guangyong
    Yao, Qing
    Long, Chubing
    Yi, Pengcheng
    Song, Jiali
    Wu, Luojia
    Wan, Wei
    Rao, Xiuqin
    Lin, Yue
    Wei, Gen
    Ying, Jun
    Hua, Fuzhou
    NEURAL REGENERATION RESEARCH, 2025, 20 (03) : 779 - 793
  • [8] Plasmapheresis:: Its use in multiple sclerosis and other demyelinating processes of the central nervous system.: An observation study
    Meca-Lallana, JE
    Rodríguez-Hilario, H
    Martínez-Vidal, S
    Saura-Luján, I
    Carretón-Ballester, A
    Escribano-Soriano, JB
    Martín-Fernández, J
    Genovés-Aleixandre, A
    Mateo-Bosch, E
    Fernández-Barreiro, A
    REVISTA DE NEUROLOGIA, 2003, 37 (10) : 917 - 926
  • [9] FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
    Brinkmann, Volker
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (05) : 1173 - 1182
  • [10] Metallothionein expression in the central nervous system of multiple sclerosis patients
    Penkowa, M
    Espejo, C
    Ortega-Aznar, A
    Hidalgo, J
    Montalban, X
    Cáceres, EMM
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (06) : 1258 - 1266